Placeholder

Propranolol Hydrochloride

CAS No:
318-98-9 Categories: , ,
  • # LGM Pharma is a Propranolol Hydrochloride CAS# 318-98-9 API supplier distributor based in the USA. Inquire about DMF, cGMP, price, availability, samples, sourcing, purity and more.
  • # Questions? Call our customer API support number 1-(800)-881-8210.
  • # LGM Pharma offers this active ingredient but not the finished dosage forms.
  • Inquire about this product >>

Product Details:

  • Product Name: Propranolol Hydrochloride
  • CAS #: 318-98-9
  • Mode of Action:

    Propranolol competes with sympathomimetic neurotransmitters such as catecholamines for binding at beta(1)-adrenergic receptors in the heart, inhibiting sympathetic stimulation. This results in a reduction in resting heart rate, cardiac output, systolic and diastolic blood pressure, and reflex orthostatic hypotension.

  • Pharmacodynamics:

    Propranolol, the prototype of the beta-adrenergic receptor antagonists, is a competitive, nonselective beta-blocker similar to nadolol without intrinsic sympathomimetic activity. Propanolol is a racemic compound; the l-isomer is responsible for adrenergic blocking activity.

  • Metabolism:

    Hepatic

  • Toxicity:

    Symptoms of overdose include bradycardia, cardiac failure, hypotension, and brochospasm. LD50=565 mg/kg (orally in mice).

  • IUPAC: (RS)-1-(isopropylamino)-3-(1-naphthyloxy)propan-2-ol
  • ATC: C07AA05
  • PubChem: 4946
  • DrugBank: DB00571
  • Formula: C16H21N1O2
  • Molecular Mass: 259.34
  • Synonyms: (+-)-1-(Isopropylamino)-3-(1-naphthyloxy)-2-propanol hydrochloride, 1-(1-Naphthyloxy)-2-hydroxy-3-isopropylaminopropane hydrochloride, 1-(Isopropylamino)-3-(1-naphthoxy)-propan-2-ol hydrochloride, 1-(Isopropylamino)-3-(1-naphthyloxy)-2-propanol hydrochloride, 1-(Isopropylamino)-3-(alpha-naphthoxy)-2-propanol hydrochloride, 1-Isopropylamino-3-(1-naphthoxy)-propan-2-ol-hydrochloride, 2-Propanol, 1-((1-methylethyl)amino)-3-(1-naphthalenyloxy)-, hydrochloride, 2-Propanol, 1-((1-methylethyl)amino)-3-(1-naphthalenyloxy)-, hydrochloride, (+-)-, Acifol, Anaprilin, Anapriline, Angilol, Apsolol, Arcablock, Artensol, Avlocardyl, AY 64043, Beprane, Berkolol, beta Neg, beta-NEG, Beta-Tablinen, Beta-Timelets, Biocard, Blocaryl, Cardinol, Caridolol, CCRIS 1105, Cinlol, Ciplar, Corbeta, d,l-Propranolol hydrochloride, Deralin, Detensol, Dibudinate, DL-Anapriline, DL-Propranolol hydrochloride, Dociton, Dumopranol, Duranol, Duraprox, Efectolol, EINECS 206-268-7, EINECS 222-501-5, Elbrol, Emforal, Farprolol, Frekven, Half-Inderal, HemangeolHemangeol, Hemipralon, Herzbase, Herzul, HSDB 3176, I 2065, ICI 45520, Ikopal, Inderal, Inderal LA, Inderalici, Inderex, Indermigran, Indobloc, Innopran, InnoPran XL, KEMI, Kidoral, Naprilin, Nedis, Nelderal, Noloten, Novopranol, NSC 91523, NSC-91523, Obsidan, Oposim, Panolol, Prandol, Pranix, Prano-Puren, Proberta LA, Procor, Pronovan, Propabloc, Propadex, Propalong, Propayerst, Prophylux, Propra vt ct, Proprahexal, Propral, Propranolol chloride, Propranolol HCl, Propranolol hydrochloride, Propranolol hydrochloride intensol, Propranovitan, Propranur, Propraratiopharm, Prosin, Pur-Bloka, Pylapron, R+C5989educor, Rapynogen, Sagittol, Sawatol, Scandrug, Sinal, Sloprolol, Sudenol, Tensiflex, Tesnol, Tiperal, Tonum, UNII-F8A3652H1V
  • SMILES: c12c(OCC(CNC(C)C)O)cccc1cccc2.Cl
  • AHFS Code: 24:24.0
  • InChl: 1S/C16H21NO2.ClH/c1-12(2)17-10-14(18)11-19-16-9-5-7-13-6-3-4-8-15(13)16;/h3-9,12,14,17-18H,10-11H2,1-2H3;1H
  • General Reference:

    1. Brunet A, Orr SP, Tremblay J, Robertson K, Nader K, Pitman RK: Effect of post-retrieval propranolol on psychophysiologic responding during subsequent script-driven traumatic imagery in post-traumatic stress disorder. J Psychiatr Res. 2007 Jun 21;. Pubmed
    2. Ohnishi ST, Sadanaga KK, Katsuoka M, Weidanz WP: Effects of membrane acting-drugs on plasmodium species and sickle cell erythrocytes. Mol Cell Biochem. 1989 Nov 23-Dec 19;91(1-2):159-65. Pubmed
    3. Singh N, Puri SK: Interaction between chloroquine and diverse pharmacological agents in chloroquine resistant Plasmodium yoelii nigeriensis. Acta Trop. 2000 Nov 2;77(2):185-93. Pubmed
    4. Murphy SC, Harrison T, Hamm HE, Lomasney JW, Mohandas N, Haldar K: Erythrocyte G protein as a novel target for malarial chemotherapy. PLoS Med. 2006 Dec;3(12):e528. Pubmed

Products currently covered by valid US Patents are offered for R&D use in accordance with 35 USC 271(e)+A13(1). Any patent infringement and resulting liability is solely at buyer risk.

API’s From Quality Manufacturers:

  • Streamlined API supply towards initial research stages as well as larger quantities of cGMP material for clinical trials and product commercialization
  • Premium quality GMP certified and fully accredited API manufacturing plants

 

  • Technical packages as well as access to filed DMF,
    ASMF or CEP (subject to availability)
  • Regulatory and technical assistance towards any
    submission type based on specific customer requirements

LGM Pharma Acquires CDMO

On July 27, 2020, LGM Pharma announced its acquisition of the formulation development and drug product contract manufacturing business of Nexgen Pharma, Inc. As a result, you will notice our new logo and visuals throughout the website. We’re working on updates to reflect the exciting, expanded CDMO capabilities and services we now can offer you.

This website uses cookies. By using our site, you agree to our terms of service